IRLAB Therapeutics AB (OSTO:IRLAB A) Institutional Ownership: 2.04% (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:IRLAB A IRLAB Therapeutics AB OSTO:IRLAB A
35 GF Score
Price kr1.39
GF Value kr11.72
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IRLAB Therapeutics AB Institutional Ownership?

IRLAB Therapeutics AB OSTO:IRLAB A -0.43% 35 Institutional Ownership is 2.04% as of Jul. 15, 2026. GuruFocus rates OSTO:IRLAB A with a GF Score™ of 35/100 and a GF Value™ of kr11.72 (Possible Value Trap). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, IRLAB Therapeutics AB's institutional ownership is 2.04%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, IRLAB Therapeutics AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, IRLAB Therapeutics AB's Float Percentage Of Total Shares Outstanding is 0.00%.

IRLAB Therapeutics AB Institutional Ownership Historical Data

* Premium members only.

The historical data trend for IRLAB Therapeutics AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB Institutional Ownership Chart

IRLAB Therapeutics AB Historical Data

The historical data trend for IRLAB Therapeutics AB can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 1.67 1.67 1.65 1.65 1.65 1.66 1.66 1.62 1.62 2.04
OSTO:IRLAB A
35GF Score
IRLAB Therapeutics AB OSTO:IRLAB A
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IRLAB Therapeutics AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 2.04% mean?
IRLAB Therapeutics AB (OSTO:IRLAB A) has a Institutional Ownership of 2.04% as of Jul. 15, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on IRLAB Therapeutics AB and its competitors.
Is IRLAB Therapeutics AB's Institutional Ownership too high?
IRLAB Therapeutics AB's current Institutional Ownership is 2.04%. Overall, IRLAB Therapeutics AB has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's Institutional Ownership compare to VRTX and REGN?
IRLAB Therapeutics AB's Institutional Ownership of 2.04% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on IRLAB Therapeutics AB and its competitors. IRLAB Therapeutics AB's current Institutional Ownership is 2.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.72, compared to a current price of kr1.39 — trading 88.2% below its estimated fair value. The current Institutional Ownership is 2.04%. IRLAB Therapeutics AB's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current Institutional Ownership is 2.04% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.39 is trading 88.2% below its estimated GF Value™ of kr11.72. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

  • Institutional Ownership: 2.04%
  • GF Value™: kr11.72 vs. price of kr1.39 (88.2% below fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRLAB Therapeutics AB Business Description

Other Exchanges 6IRA:Germany
Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
35GF Score

Get the complete analysis for OSTO:IRLAB A

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.39
Price
kr11.72
GF Value